Study Finds Safety Test Results on Children's Drugs Don't Always Reach Practitioners

From: AANA Journal | Date: November 1, 2006| Author: Anonymous | Copyright information

Hundreds of drugs that have been prescribed for children may not be safe or effective for pediatric use or may require different doses than currently suggested, but some of this information may not be reaching the medical community, according to a study by Duke University Medical Center researchers. Such drugs include antidepressants, antiseizure medications, and sedatives.

The study team examined drugs covered by a congressionally mandated program known as "pediatric exclusivity," thr...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

SAFETY AND INNOVATION IN PEDIATRIC THERAPIES:LORI REILLY
Congressional Testimony ; Congressional Testimony 05-22-2007 Statement of Lori Reilly Vice President Policy & Research Pharmaceutical Research and Manufacturers of America (PhRMA) Committee on House Energy and Commerce Subcommittee on Health May 22, 2007 Mr. Chairman, Rep. Deal, and Members of the Subcommittee: Thank
Pediatric Exclusivity Program Renewed.(Brief Article)
Chemical Market Reporter ; THE HOUSE OF Representatives has voted to renew a program that gives pharmaceutical companies six months of exclusive market rights if they test and label their products for children. The bill, passed on a 338-86 vote, expands and extends incentives Congress established in 1997 to encourage
Kid Tested, Government Approved?
Pharmaceutical Executive ; Critics claim pharma is too richly rewarded for studying drugs in children. Now, several proposals are on the table that just might change that. As the industry focuses its attention on the upcoming renewal of the Prescription Drug User Fee Act (PDUFA), there is a tendency to overlook two other
Exclusivity program has mixed economic results.(Practice Trends)
Pediatric News ; As an incentive for pharmaceutical companies to conduct clinical trials in children, the Pediatric Exclusivity Program yields variable results, ranging from a generous economic net gain to a net loss, according to a study by Dr. Jennifer Li of Duke Clinical Research Institute, Durham, N.C., and
FDA backs down on pediatric studies. (Washington Insider).(Pediatric exclusivity program.)(Government Activity)(Brief Article)
Medical Marketing & Media ; * Faced with mounting pressure from consumer groups and Congress, the FDA backpedaled in April and withdrew a federal court request it had made the previous month to stay proceedings while it considered revising its pediatric drug studies rule. The agency now, with support from HHS, is launching a
Senators question FDA pediatric rule stay. (Washington Insider).(Brief Article)
Medical Marketing & Media ; * Twelve U.S. senators have requested a briefing on the FDA'S decision to stay its pediatric studies rule, a move they question because the rule complements the recently reauthorized Best Pharmaceuticals for Children Act (FDA's pediatric exclusivity program). In a March 26 letter to Health and
Senate reauthorizes pediatric exclusivity. (Washington Insider).(Best Pharmaceuticals for Children Act, United States. Food and Drug Administration program)(Brief Article)
Medical Marketing & Media ; * The U.S. Senate in October passed a bill called Best Pharmaceuticals for Children Act reauthorizing the FDA'S pediatric exclusivity program. Language was also added to the bill that would allow generic drug makers to carve out generic drug labeling absent any exclusivity-protected pediatric
Roche AG.(Accutane receives additional six months of marketing exclusivity)(Brief Article)
Medical Marketing & Media ; Roche AG was granted six additional months of marketing exclusivity for its acne drug Accutane (isotretinoin). Through the FDA'S pediatric exclusivity program, Roche will be able to market Accurane in the United States until February 7, 2002. Study results showed that the safety and efficacy of
Senate committee passes pediatric program.(Brief Article)
Medical Marketing & Media ; The Senate Health, Education, Labor and Pensions Committee on August 1 unanimously passed legislation that reauthorizes the FDA's pediatric exclusivity program. The measure, Best Pharmaceuticals for Children Act of 2001, was sponsored by Senators Chris Dodd (D. CT) and Mike DeWine (R OH). It
Buying time
Pharmaceutical Executive ; US PHARMA COMPANIES CAN CONTINUE TO BENEFIT FROM AN EXTENDED PEDIATRIC EXCLUSIVITY PROVISION. Marketing exclusivity is the life-- blood of the US pharma industry. Every day a brand-name drug is on the market without generic competition brings tremendous revenue to its manufacturer. Consider, for